{{ variable.name }}
Instruction Manual
【 Common Name 】 Vinaiklar Tablets
[Brand Name] ALIVINEKLA
【 Main Ingredients 】 Vinaclat...... 100mg.
【 Indications 】
Suitable for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL);
Combination therapy with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older, or for patients with comorbidities that cannot be treated with intensified induction chemotherapy.
[Usage and Dosage]
Recommended dose for chronic lymphocytic leukemia/small lymphocytic lymphoma
Single drug treatment: First, take the medication according to the table below. After 5 weeks, maintain the dose at 400mg once a day until the disease progresses or unacceptable toxicity occurs.
[Taboo]
CLL/SLL patients should not use potent CYP3A inhibitors simultaneously during the initial and ascending phases.
【 Precautions 】
Tumor Lysis Syndrome (TLS): Expected TLS; Assess the risk of all patients.
Neutropenia: Monitor blood count, discontinue medication and administer the same or reduced dose.
Infection: Monitor the signs and symptoms of infection and seek timely treatment; Suspend level 3 and 4 infections until symptoms improve.
Immunity: Do not administer attenuated live vaccines before, during, or after treatment with Vinaclat until B cells have recovered.
Embryo fetal toxicity: may lead to embryo fetal injury; It is recommended not to breastfeed during lactation.
Adverse reactions include neutropenia, thrombocytopenia, anemia, nausea, abdominal pain, cough, and oropharyngeal pain.
[Appearance] White tablet.
【 Validity Period 】 2 years from the date of production.
[Packaging] 120 tablets/bottle.
[Storage]
Sealed, dry and stored at no more than 30 ℃.
Please keep out of reach of children.
[Production Enterprise]
Laos Alliance Pharmaceutical Group Factory